Form 4: Evolent Health Director Richard Jelinek Acquires 30,000 Shares of Class A Common Stock

Richard Jelinek, a director of Evolent Health, Inc., recently purchased 30,000 shares of Class A Common Stock through revocable trusts at prices around $9.10 per share.

Summary

• On March 7, 2025, Richard M Jelinek, a director of Evolent Health, Inc., acquired 30,000 shares of Class A Common Stock.
• The purchases were made through two separate transactions, each involving 15,000 shares.
• One transaction was executed at a price of $9.16 per share, and the other at $9.09 per share.
• The shares were acquired indirectly through the Richard M Jelinek Revocable Trust and the Richard M Jelinek GST.
• Following these transactions, Jelinek directly owns 14,458 shares and indirectly owns 30,000 shares through the trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's stock purchase, which can be interpreted as a positive signal but doesn't inherently indicate strong positive or negative sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common among publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The stock purchase by a director could have a slightly positive impact on shareholder sentiment.

Key Dates